Literature DB >> 33657207

How I manage acquired pure red cell aplasia in adults.

Carmelo Gurnari1,2, Jaroslaw P Maciejewski1.   

Abstract

Pure red cell aplasia (PRCA) is a rare hematological disorder with multiple etiologies. The multifaceted nature of this disease is emphasized by the variety of concomitant clinical features. Classic idiopathic presentation aside, prompt recognition of pathogenetic clues is important because of their diagnostic and therapeutic implications. As a consequence, treatment of PRCA is diverse and strictly dependent on the presented clinical scenario. Here, we propose a series of clinical vignettes that showcase instructive representative situations derived from our routine clinical practice. Using these illustrative clinical cases, we review the diagnostic workup needed for a precise diagnosis and the currently available therapeutic options, discussing their applications in regard to the various PRCA-associated conditions and individual patients' characteristics. Finally, we propose a treatment algorithm that may offer guidance for personalized therapeutic recommendations.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 33657207      PMCID: PMC8057257          DOI: 10.1182/blood.2021010898

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  85 in total

1.  Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia.

Authors:  Michael J Clemente; Marcin W Wlodarski; Hideki Makishima; Aaron D Viny; Isabell Bretschneider; Mohammad Shaik; Nelli Bejanyan; Alan E Lichtin; Eric D Hsi; Eric D His; Ronald L Paquette; Thomas P Loughran; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-08-24       Impact factor: 22.113

2.  Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy.

Authors:  G Kurtzman; N Frickhofen; J Kimball; D W Jenkins; A W Nienhuis; N S Young
Journal:  N Engl J Med       Date:  1989-08-24       Impact factor: 91.245

3.  Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

Authors:  Charles L Bennett; Denis Cournoyer; Kenneth R Carson; Jerome Rossert; Stefano Luminari; Andrew M Evens; Francesco Locatelli; Steven M Belknap; June M McKoy; E Alison Lyons; Benjamin Kim; Rishi Sharma; Stacey Costello; Edwin B Toffelmire; George A Wells; Hans A Messner; Paul R Yarnold; Steven M Trifilio; Dennis W Raisch; Timothy M Kuzel; Allen Nissenson; Lay-Cheng Lim; Martin S Tallman; Nicole Casadevall
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

Review 4.  Pure red cell aplasia.

Authors:  Robert T Means
Journal:  Blood       Date:  2016-11-24       Impact factor: 22.113

Review 5.  How I treat Diamond-Blackfan anemia.

Authors:  Adrianna Vlachos; Ellen Muir
Journal:  Blood       Date:  2010-07-22       Impact factor: 22.113

6.  Effect of tacrolimus in a patient with pure red-cell aplasia.

Authors:  S Yoshida; T Konishi; T Nishizawa; Y Yoshida
Journal:  Clin Lab Haematol       Date:  2005-02

7.  Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation.

Authors:  C D Bolan; S F Leitman; L M Griffith; R A Wesley; J L Procter; D F Stroncek; A J Barrett; R W Childs
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

8.  STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia.

Authors:  Fumihiro Ishida; Kazuyuki Matsuda; Nodoka Sekiguchi; Hideki Makishima; Chiaki Taira; Kayoko Momose; Sayaka Nishina; Noriko Senoo; Hitoshi Sakai; Toshiro Ito; Yok-Lam Kwong
Journal:  Cancer Sci       Date:  2014-01-22       Impact factor: 6.716

Review 9.  Acquired pure red cell aplasia: updated review of treatment.

Authors:  Kenichi Sawada; Naohito Fujishima; Makoto Hirokawa
Journal:  Br J Haematol       Date:  2008-05-28       Impact factor: 6.998

10.  Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.

Authors:  Bogdan Dumitriu; Sawa Ito; Xingmin Feng; Nicole Stephens; Muharrem Yunce; Sachiko Kajigaya; Joseph J Melenhorst; Olga Rios; Priscila Scheinberg; Fariba Chinian; Keyvan Keyvanfar; Minoo Battiwalla; Colin O Wu; Irina Maric; Liqiang Xi; Mark Raffeld; Pawel Muranski; Danielle M Townsley; Neal S Young; Austin J Barrett; Phillip Scheinberg
Journal:  Lancet Haematol       Date:  2015-12-17       Impact factor: 18.959

View more
  3 in total

1.  Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.

Authors:  Xuemei Wu; Lang Cheng; Xiaoqing Liu; Yu Sun; Bingzong Li; Guangsheng He; Jianyong Li
Journal:  Ann Hematol       Date:  2022-04-23       Impact factor: 3.673

2.  Case Report: Large Granular Lymphocyte Leukemia (LGLL)-A Case Series of Challenging Presentations.

Authors:  Natali Pflug; Annika Littauer; David Beverungen; Aleksandra Sretenovic; Linus Wahnschaffe; Till Braun; Annika Dechow; Dennis Jungherz; Moritz Otte; Astrid Monecke; Enrica Bach; Georg-Nikolaus Franke; Sebastian Schwind; Madlen Jentzsch; Uwe Platzbecker; Marco Herling; Vladan Vucinic
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

3.  A 46-Year-Old Thai Woman with Secondary Acquired Pure Red Cell Aplasia Due to Treatment with Recombinant Erythropoietin While on Dialysis for End-Stage Renal Disease Who Recovered Following ABO-Incompatible Kidney Transplantation.

Authors:  Rungthiwa Kitpermkiat; Sansanee Thotsiri; Nuttaporn Arpornsujaritkun; Premsant Sangkum; Pichika Chantrathammachart; Pimpun Kitpoka; Duangtawan Thammanichanond; Tanist Virankabutra; Surasak Kantachuvesiri
Journal:  Am J Case Rep       Date:  2022-07-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.